<DOC>
	<DOCNO>NCT02826356</DOCNO>
	<brief_summary>Specific treatment angiotensin-converting-enzyme inhibitor ( ACE-I ) angiotensin-receptor-blocker ( ARB ) -induced angioedema exist . Early access treatment challenge expensive short shelf live make illusory emergency department ( ED ) stock . The aim retrospective study define , patient confirm ACE-I ARB-induced angioedema , step care , specific treatment administer . The second objective analyse availability treatment area around Lyon , France factor may influence .</brief_summary>
	<brief_title>Analysis Availability Treatments ACE-I ARB-induced Angioedema</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<criteria>Every patient follow first time reference center severe confirm ACEI ARBinduced angioedema . Data analyze patient attend either specialized angioedema consultation hospitalization intensive care unit . Severe attack define either localization shoulder severe abdominal attack . Patients receive specific treatment ( icatibant , C1inhibitor concentrate ) exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Angioedema</keyword>
	<keyword>Emergency treatment</keyword>
	<keyword>Treatment availability</keyword>
	<keyword>Health Equity</keyword>
</DOC>